Walid Abi-Saab - 30 Oct 2026 Form 4 Insider Report for uniQure N.V. (QURE)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 17:09:26 UTC
Prior SEC filing
02 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christian Klemt, Attorney-in-Fact
Filing notes and source

Key filing fact

Walid Abi-Saab filed Form 4 for uniQure N.V. (QURE) on 03 Nov 2026.

Key facts

  • This page summarizes Walid Abi-Saab's Form 4 filing for uniQure N.V. (QURE).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 17:09.

Change

  • Previous filing in this sequence was filed on 02 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985973 Primary reporting owner

Abi-Saab Walid

Relationship
Chief Medical Officer
Address
C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, NETHERLANDS
Signature
/s/ Christian Klemt, Attorney-in-Fact
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QURE transaction

Ordinary Shares

Award

Transaction value
Shares
+18,750
Change %
+13%
Price
$0.000000*
Shares after
166,985
Date
30 Oct 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents performance-based restricted share units ("PRSUs") granted to the Reporting Person on January 20, 2026 under the Issuer's 2014 Share Incentive Plan, as amended and restated, which were earned on October 30, 2026 as the result of the satisfaction of certain regulatory milestones. Each PRSU represents the contingent right to receive one Ordinary Share. These shares will vest on the later of (i) 10 business days after the receipt of certain regulatory clearance and (ii) January 20, 2027, subject to the Reporting Person's continued employment by the Issuer through such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .